Synthesis, in vitro and in vivo activity of thiamine antagonist transketolase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 6, 2008, Pages 2206-2210

  Thomas, Allen A ^a   Le Huerou, Y ^a   De Meese, J ^a   Gunawardana, Indrani ^a   Kaplan, Tomas ^a   Romoff, Todd T ^a   Gonzales, Stephen S ^a   Condroski, Kevin ^a   Boyd, Steven A ^a   Ballard, Josh ^a   Bernat, Bryan ^a   DeWolf, Walter ^a   Han, May ^b   Lee, Patrice ^a   Lemieux, Christine ^a   Pedersen, Robin ^b   Pheneger, Jed ^a   Poch, Greg ^a   Smith, Darin ^a   Sullivan, Francis ^a   Weiler, Solly ^b   Wright, S Kirk ^b   Lin, Jie ^b   Brandhuber, Barb ^a   Vigers, Guy ^a   more..

^a ARRAY BIOPHARMA INC   (United States)

^b AVEO ONCOLOGY   (United States)

Author keywords

Cancer; Metabolism; Pyrophosphate; Thiamine; Transketolase

Indexed keywords

3 (6 METHYL 2 AMINOPYRIDIN 3 YLMETHYL) 5 (2 HYDROXYETHYL) 4 METHYLTHIAZOL 3 IUM CHLORIDE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; OXOGLUTARATE DEHYDROGENASE; PENTOSE PHOSPHATE; RIBOSE; THIAMINE DERIVATIVE; TRANSKETOLASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG POTENCY; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; SPLEEN; STRUCTURE ACTIVITY RELATION; TUMOR CELL; TUMOR XENOGRAFT;

ANIMALS; COLONIC NEOPLASMS; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; GLUCOSEPHOSPHATE DEHYDROGENASE; HUMANS; KETOGLUTARATE DEHYDROGENASE COMPLEX; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, NUDE; MOLECULAR STRUCTURE; OXYTHIAMINE; PHOSPHORYLATION; SPLEEN; STRUCTURE-ACTIVITY RELATIONSHIP; THIAMINE; TRANSKETOLASE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 40749095542     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.11.101     Document Type: Article

References (19)

1. Boros L.G., Torday J.S., Lim S., Bassilian S., Cascante M., and Lee W.-N.P. Cancer Res. 60 (2000) 1183
2. Cascante M., Centelles J.J., Veech R.L., Lee W.-N.P., and Boros L.G. Nutr. Cancer 36 (2000) 150
3. Rais B., Comin B., Puigjaner J., Brandes J.L., Creppy E., Saboureau D., Ennamany R., Lee W.N., Boros L.G., and Cascante M. FEBS Lett. 456 (1999) 113
4. Subramanian V.S., Marchant J.S., Parker I., and Said H.M. J. Biol. Chem. 278 (2003) 3976
5. Baker L.-J., Dorocke J.A., Harris R.A., and Timm D.E. Structure 9 (2001) 539
6. Du M.X., Sim J., Fang L., Zheng Y., Koh S., Stratton J., Pons J., Wang J.J.-X., and Carte B. J. Biomol. Screen 9 (2004) 427
7. Solovjeva O.N., and Kochetov G.A. FEBS Lett. 462 (1999) 246
8. Boros L.G. Cancer Res. 58 (1998) 3188
9. Boros L.G., Puigjaner J., Cascante M., Lee W.-N.P., Brandes J.L., Bassilian S., Yusuf F.I., Williams R.D., Muscarella P., Melvin W.S., and Schirmer W.J. Cancer Res. 57 (1997) 4242
10. Kochetov G.A., Izotova A.E., and Meshalkina L.E. Biochem. Biophys. Res. Commun. 43 (1971) 1198
11. This compound has been previously reported. Matsukawa T., and Matsuno T. Yakugaku Zasshi 64 (1944) 145
12. Dornow A., and Hargesheimer A. Chem. Ber. 86 (1953) 461
13. Ostrovskii Y.M., Chernikevich I.P., Voskoboev A.I., and Shellenberger A. Bioorg. Khim. 3 (1977) 1083
14. Meshalkina L.E., Golbik R., Usmanov R.A., Neef H., Schellenberger A., and Kochetov G.A. Dokl. Akad. Nauk SSSR 307 (1989) 486
15. Boyd, S. A. WO2005095391.
16. Gutowski J.A. Methods Enzymol. 62 (1979) 120
17. Prior to performing the TPPK/apo-TK assay, each compound was evaluated for its ability to be pyrophosphorylated by TPPK using thiamine as a control substrate. The extent of substrate pyrophosphorylation relative to thiamine pyrophosphorylation was determined prior to competition with TPP in inhibiting TK activity according to methods described in WO2005/095391.
18. Gyuris, J.; O'Hagan, R. C.; Han, M.; Robinson, M.; Weiler, S., WO2005094803.
19. Though other compounds (e.g., 13 and 26) demonstrated comparable or better cellular potency to compound 1, the latter was tested in the xenograft model due to its synthesis being amenable to scaleup at the time the xenograft experiments were performed.